Vaccines
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma Virus (RSV) and Cancer
Immune Response Against Viral Pathogens
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 28, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Zhi-Wu Xia1,2, Qi Tang3, Jun-Jie Pan3
1College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.
A new mRNA vaccine for Respiratory Syncytial Virus (RSV) shows promise. Optimized for stability and efficacy, it induced strong immune responses in mice, suggesting potential for a safe and effective RSV vaccine.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: